Li et al. revealed that the dysregulation of miR-27a is involved in the development of paclitaxel resistance in ovarian cancer cells, which involves the regulation of MDR1/P-gp expression through the targeting of HIPK218. This evidence concerns the gene PGP and ovarian carcinoma.